ADME pharmacogenetics: future outlook for Russia

• Published in: Pharmacogenomics Vol. 20; no. 11; pp. 847 - 865
• Main Authors: Mirzaev, Karin B, Fedorinov, Denis S, Ivashchenko, Dmitry V, Sychev, Dmitry A
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-07-2019
• Subjects: ADME; Alleles; Anticoagulants - adverse effects; Anticoagulants - therapeutic use; Biotransformation; Cardiac arrhythmia; cardiology; Clinical trials; Cytochrome P-450 Enzyme System - genetics; Disease; Drug dosages; Enzymes; Excretion; Genes; Genomics; Genotype; Humans; Inactivation, Metabolic - genetics; Joint surgery; Metabolism; Minority & ethnic groups; Oxidation; P450; Patients; personalized medicine; Pharmacogenetics; Pharmacogenetics - trends; pharmacogenomics; Polymorphism; Population; Precision medicine; Russia; Russia - epidemiology; Search strategies; Studies; Systematic review; Warfarin; Warfarin - adverse effects; Warfarin - therapeutic use; Russia; P450; pharmacogenomics; ADME; cardiology; Russia; personalized medicine
• ISSN: 1462-2416; 1744-8042
• DOI: 10.2217/pgs-2019-0013

This systematic review reflects the results of pharmacogenetic studies in the Russian Federation aimed at studying the genes involved in the drug biotransformation system. The works of Russian researchers found by us are mostly devoted to microsomal liver oxidation enzymes (metabolism) and membrane transporter systems (absorption and excretion). This review presents population-ethnic and associative clinical studies on the genes of the
system, noncytochrome oxidation enzymes (
,
), membrane transporter system genes (
,
) and warfarin biotransformation enzymes (
,
). The information is structured in the form of 11 tables, divided by regions of the Russian Federation.